Abiraterone ACetate, Advanced Prostate Cancer
Conditions
Keywords
metastatic Castration Resistant Prostate Cancer, Abiraterone Acetate, Biomarkers
Brief summary
PROSABI is a prospective multicentre observational study in metastatic Castration-Resistant Prostate Cancer (mCRPC), designed to explore prognostic biomarkers in patients undergoing treatment with abiraterone
Detailed description
This study is a prospective biomarker study of patients with mCRPC undergoing treatment with abiraterone as standard of care treatment. The participants will undergo serial pre- and post-therapy blood collection for biomarker analysis as part of the primary objective of the study.
Interventions
None listed
Sponsors
Centro Nacional de Investigaciones Oncologicas CARLOS III
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
1. Male age ≥ 18 years 2. Histologically confirmed adenocarcinome of the prostate 3. ECOG Performance Status ≤ 2 4. Castration resistance must be documented with surgical or medical castration with serum testosterone \< 50 ng/mL (\< 2.0 nM). 5. Men diagnosed with at least one metastatic lesion on CT or bone scan. 6. Documented biochemical and/or radiographic progression to previous treatment according to PCWG2 criteria. 7. Patients who are candidates for standard of care treatment with abiraterone acetate: 1000 mg every 24 hours plus prednisone 5 mg every 12 hours. 8. Availability of formalin-fixed paraffin-embedded blocks from the prostate biopsy and/or radical prostatectomy. 9. Acceptable hematological, hepatic and renal functions.9. Acceptable haematological, hepatic and renal functions.
Exclusion criteria
1. Previous cancer diagnosis, except those patients who had a localized malignant tumour and who are five years cancer-free or those diagnosed with skin cancers (of non-melanoma type) or excised in situ carcinomas. 2. Any condition or reason that, in the opinion of the Investigator, interferes with the ability of the patient to participate in the trial, which places the patient at undue risk, or complicates the interpretation of safety data
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To validate the independent prognostic value of the gene-expression signature from peripheral blood described by Olmos et al (Lancet Oncol 2012) on overall survival of mCRPC patients | Initially 48 months, currently 60 months |
Secondary
| Measure | Time frame |
|---|---|
| To analyze the prognostic value of early changes in the gene-expression signature described by Olmos et al | Initially 48 months, currently 60 months |
| To compare the prognostic value of the gene-expression signature described by Olmos et al versus the gene-expression signature described by Ross et al (Lancet Oncol, 2012) | Initially 48 months, currently 60 months |
| To validate the prognostic value of classical nomograms designed to assess the outcomes of mCRPC patients in these patients | Initially 48 months, currently 60 months |
| To analyze the prognostic value of the gene-expression signature described by Olmos et al on biochemical and radiological progression-free survival | Initially 48 months, currently 60 months |
| To analyze the prognostic value of AR splicing variants, serum chromogranine and serum testosterone levels measured by ultrasensitive method in these both cohorts of patients | Initially 48 months, currently 60 months |
| To correlate the presence of somatic and/or germinal mutations with the outcomes of these patients | Initially 48 months, currently 60 months |
| To analyze the prognostic value of TMPRSS2-ERG rearrengement and PTEN loss in these cohorts | Initially 48 months, currently 60 months |
Countries
Spain
Outcome results
None listed